The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 7, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Type 2 DiabetesOsteopenia
Interventions
DRUG

oral Semaglutide/Rybelsus

Weeks 1-4: 3 mg of oral semaglutide once daily. Weeks 5-52: 7 mg of semaglutide once daily as maintenance dose. Dose may be increased to 14 mg of semaglutide once daily as maintenance dose after 2 months if glucose levels are out of range.

DRUG

Placebo

Weeks 1-4: 3 mg of oral placebo once daily. Weeks 5-52: 7 mg of placebo once daily as maintenance dose. Dose may be increased to 14 mg of placebo once daily as maintenance dose after 2 months if glucose levels are out of range.

Trial Locations (1)

5000

RECRUITING

Odense University Hospital, Odense

All Listed Sponsors
lead

Odense University Hospital

OTHER